Price T Rowe Associates Inc Summit Therapeutics Inc. Transaction History
Price T Rowe Associates Inc
- $816 Billion
- Q1 2024
A detailed history of Price T Rowe Associates Inc transactions in Summit Therapeutics Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 33,145 shares of SMMT stock, worth $228,369. This represents 0.0% of its overall portfolio holdings.
Number of Shares
33,145
Previous 28,006
18.35%
Holding current value
$228,369
Previous $74,000
86.49%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding SMMT
# of Institutions
107Shares Held
41.3MCall Options Held
103KPut Options Held
29.9K-
Black Rock Inc. New York, NY9.82MShares$67.7 Million0.0% of portfolio
-
State Street Corp Boston, MA8.11MShares$55.9 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.27MShares$50.1 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA3.15MShares$21.7 Million0.0% of portfolio
-
Northern Trust Corp Chicago, IL1.07MShares$7.39 Million0.0% of portfolio
About Summit Therapeutics Inc.
- Ticker SMMT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 201,215,008
- Market Cap $1.39B
- Description
- Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...